enfortumab vedotin,pembrolizumab
merck,astellas,seagen
['bladder', ' vedo', 'enfortumab', 'pembro']
enfortumab vedotin + pembrolizumab shrank locally advanced and metastatic #bladdercancer tumors in 64.5% of patients ( than standard treatments); and 15.6% saw tumors disappear completely, reported at #esmo22. 
The official account of Memorial Sloan Kettering Cancer Center, the Sloan Kettering Institute, and Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences